| Strain Name |
C57BL/6N-Tg(RP11-634C1)1Bcgen/Bcgen
|
Common Name | B-Tg(hLILRB2/hLILRB3) mice |
| Background | C57BL/6N | Catalog number | 110858 |
|
Related Genes |
LILRB2: ILT4, LIR2, CD85D, ILT-4, LIR-2, MIR10, MIR-10 LILRB3: HL9, ILT5, LIR3, PIRB, CD85A, ILT-5, LIR-3, PIR-B, LILRA6 |
||
|
NCBI Gene ID |
10288,11025 |
||
Protein expression analysis (F3)
Strain specific LILRB3 expression analysis in transgenic B-Tg(hLILRB2-hLILRB3) mice by flow cytometry. Dendritic cells and macrophages of blood were collected from wild-type (+/+) and transgenic B-Tg(hLILRB2-hLILRB3) mice (Tg), and analyzed by flow cytometry with species-specific anti-human LILRB3 antibody. Human LILRB3 was both detectable in dendritic cells and macrophages from B-Tg(hLILRB2-hLILRB3) mice but not wild-type mice.
In vivo efficacy of anti-human LILRB2 antibody
Antitumor activity of anti-human LILRB2 antibody in B-Tg(hLILRB2-hLILRB3) mice. (A) Anti-human LILRB2 antibody inhibited MC38 tumor growth in B-Tg(hLILRB2-hLILRB3) mice. Murine colon cancer MC38 cells were subcutaneously implanted into B-Tg(hLILRB2-hLILRB3) mice (female, 9 week-old, n=6). Mice were grouped when tumor volume reached approximately 100-150 mm3, and treated with anti-h LILRB2 antibody in panel A. (B) Body weight changes during treatment. As shown in panel A, J19.h7 (in house) was efficacious in controlling tumor growth in B-Tg(hLILRB2-hLILRB3) mice, demonstrating they provide a powerful preclinical model for in vivo evaluation of anti-human LILRB2 antibodies. Values are expressed as mean ± SEM.
